Details of Disease

General Information of Disease (ID: DISQVJVA)

Disease Name	Oral cavity squamous cell carcinoma
Synonyms	oral squamous cell carcinoma; OCSC; oral cavity squamous cell carcinoma; oral cavity squamous cell cancer; mouth squamous cell carcinoma; scc of the oral cavity; scc of mouth; squamous cell carcinoma of oral cavity; scc of oral cavity; squamous cell carcinoma of the oral cavity; squamous cell carcinoma of the mouth; mouth scc; scc of the mouth; squamous cell carcinoma of mouth; oral cavity scc
Disease Class	2B6E: Lip/oral cavity/pharynx neoplasm
Definition	A squamous cell carcinoma arising from the oral cavity. It affects predominantly adults in their fifth and sixth decades of life and is associated with alcohol and tobacco use. Human papillomavirus is present in approximately half of the cases. It is characterized by a tendency to metastasize early to the lymph nodes. When the tumor is small, patients are often asymptomatic. Physical examination may reveal erythematous or white lesions or plaques. The majority of patients present with signs and symptoms of locally advanced disease including mucosal ulceration, pain, difficulty with speaking, chewing, and swallowing, bleeding, weight loss, and neck swelling. Patients may also present with swollen neck lymph nodes without any symptoms from the oropharyngeal tumor. The most significant prognostic factors are the size of the tumor and the lymph nodes status.
Disease Hierarchy	DISZXMVL: Oral cavity carcinoma DISYXVXC: Lip and oral cavity squamous cell carcinoma DISQVIFL: Squamous cell carcinoma DISQVJVA: Oral cavity squamous cell carcinoma
ICD Code	ICD-11 ICD-11: 2B6E.0 ICD-9 ICD-9: 199 Expand ICD-9 199
Disease Identifiers	MONDO ID MONDO_0004958 MESH ID D000077195 UMLS CUI C0585362 MedGen ID 108436 Orphanet ID 502363 SNOMED CT ID 307502000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dusquetide	DMKU3R1	Phase 3	Peptide	[1]
APG-157	DMQ8R1A	Phase 2	NA	[2]
GL-0817	DM17OZM	Phase 2	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
TNFRSF10B	TTW20TU	Limited	SusceptibilityMutation	[4]
PGRMC1	TTY3LAZ	moderate	Altered Expression	[5]
SCUBE2	TTWREQP	moderate	Altered Expression	[6]
STK32B	TT4D2GZ	moderate	Altered Expression	[6]
DOT1L	TTSZ8T1	Strong	Biomarker	[7]
ERAP2	TTVGS1C	Strong	Altered Expression	[8]
PRDX4	TTPBL9I	Strong	Biomarker	[9]
PTEN	TTXJ3W7	Strong	SomaticCausalMutation	[10]
SLC7A11	TTBZMIO	Strong	Biomarker	[11]
STAB1	TTJFEOC	Strong	Altered Expression	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DTT(s)

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
P4HA2	DE5EGK0	Strong	Biomarker	[9]
------------------------------------------------------------------------------------

This Disease Is Related to 17 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ING1	OTEZBRKW	Limited	SomaticCausalMutation	[13]
DLGAP1	OTF2PUUI	moderate	Altered Expression	[5]
BAGE3	OTBUMTWL	Strong	Biomarker	[14]
CALD1	OTNJKJ6Q	Strong	Altered Expression	[15]
CD164	OTZ7FIU8	Strong	Altered Expression	[16]
CITED4	OTR6NHI2	Strong	Altered Expression	[7]
FGA	OTMIHY80	Strong	Biomarker	[17]
GBP1	OTUM7RPJ	Strong	Biomarker	[18]
KPNA2	OTU7FOE6	Strong	Altered Expression	[19]
MAU2	OTALDF8Q	Strong	Biomarker	[20]
MLLT3	OTXH4DDG	Strong	Altered Expression	[7]
NEIL1	OTHBU5DJ	Strong	Genetic Variation	[21]
NEIL2	OTV6JEON	Strong	Genetic Variation	[21]
NID1	OTKLBLS6	Strong	Altered Expression	[22]
NID2	OTHC33FF	Strong	Biomarker	[23]
NOC2L	OTNT7R33	Strong	Biomarker	[24]
SERPINE2	OTYF5340	Strong	Altered Expression	[25]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DOT(s)

References

1	ClinicalTrials.gov (NCT03237325) DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT05312710) Phase 2 Study to Evaluate the Safety and Efficacy of APG-157 as Neoadjuvant/Induction Therapy for Patients With Head and Neck Squamous Cell Cancer (HNSCC) of the Oral Cavity and/or Oropharynx. U.S.National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Causes of death in a cohort of 260 plutonium workers.Health Phys. 1998 Sep;75(3):236-40. doi: 10.1097/00004032-199809000-00001.
5	DAP1 high expression increases risk of lymph node metastases in squamous cell carcinoma of the oral cavity.Genet Mol Res. 2015 Sep 8;14(3):10515-23. doi: 10.4238/2015.September.8.13.
6	Clinical relevance of breast cancer-related genes as potential biomarkers for oral squamous cell carcinoma.BMC Cancer. 2014 May 7;14:324. doi: 10.1186/1471-2407-14-324.
7	Characterization of Copy Number Variations in Oral Cavity Squamous Cell Carcinoma Reveals a Novel Role for MLLT3 in Cell Invasiveness.Oncologist. 2019 Dec;24(12):e1388-e1400. doi: 10.1634/theoncologist.2019-0063. Epub 2019 Jul 4.
8	Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells.Oncotarget. 2017 Jun 27;8(37):61698-61708. doi: 10.18632/oncotarget.18680. eCollection 2017 Sep 22.
9	Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology.J Proteome Res. 2011 Nov 4;10(11):4935-47. doi: 10.1021/pr200311p. Epub 2011 Sep 28.
10	Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10.Cancer Genet Cytogenet. 2002 Jan 1;132(1):20-4. doi: 10.1016/s0165-4608(01)00509-x.
11	Overexpression of cysteine-glutamate transporter and CD44 for prediction of recurrence and survival in patients with oral cavity squamous cell carcinoma.Head Neck. 2018 Nov;40(11):2340-2346. doi: 10.1002/hed.25331. Epub 2018 Oct 10.
12	Not CD68 but stabilin-1 expression is associated with the risk of recurrence in patients with oral cavity squamous cell carcinoma.Head Neck. 2019 Jul;41(7):2058-2064. doi: 10.1002/hed.25654. Epub 2019 Jan 16.
13	Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas.Cancer Res. 2000 Jun 15;60(12):3143-6.
14	Reconstruction of oral cavity defect using versatile buccinator myomucosal flaps in the treatment of cT2-3, N0 oral cavity squamous cell carcinoma: Feasibility, morbidity, and functional/oncological outcomes.Oral Oncol. 2017 Dec;75:95-99. doi: 10.1016/j.oraloncology.2017.11.007. Epub 2017 Nov 9.
15	Overexpression of caldesmon is associated with lymph node metastasis and poorer prognosis in patients with oral cavity squamous cell carcinoma.Cancer. 2013 Nov 15;119(22):4003-11. doi: 10.1002/cncr.28300. Epub 2013 Aug 20.
16	Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis.Oncol Lett. 2017 Nov;14(5):6103-6108. doi: 10.3892/ol.2017.6966. Epub 2017 Sep 15.
17	Identification of Salivary Biomarkers for Oral Cancer Detection with Untargeted and Targeted Quantitative Proteomics Approaches.Mol Cell Proteomics. 2019 Sep;18(9):1796-1806. doi: 10.1074/mcp.RA119.001530. Epub 2019 Jun 28.
18	Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis.J Proteome Res. 2011 Aug 5;10(8):3778-88. doi: 10.1021/pr2004133. Epub 2011 Jul 19.
19	Association of overexpressed karyopherin alpha 2 with poor survival and its contribution to interleukin-1-induced matrix metalloproteinase expression in oral cancer.Head Neck. 2018 Aug;40(8):1719-1733. doi: 10.1002/hed.25145. Epub 2018 Mar 15.
20	NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.Int J Mol Sci. 2018 Nov 10;19(11):3546. doi: 10.3390/ijms19113546.
21	Functional variants of the NEIL1 and NEIL2 genes and risk and progression of squamous cell carcinoma of the oral cavity and oropharynx.Clin Cancer Res. 2008 Jul 1;14(13):4345-52. doi: 10.1158/1078-0432.CCR-07-5282.
22	Proteomic Profiling of Paired Interstitial Fluids Reveals Dysregulated Pathways and Salivary NID1 as a Biomarker of Oral Cavity Squamous Cell Carcinoma.Mol Cell Proteomics. 2019 Oct;18(10):1939-1949. doi: 10.1074/mcp.RA119.001654. Epub 2019 Jul 17.
23	NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.Cancer Prev Res (Phila). 2011 Jul;4(7):1061-72. doi: 10.1158/1940-6207.CAPR-11-0006. Epub 2011 May 10.
24	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT.Mol Cancer Res. 2017 Dec;15(12):1667-1677. doi: 10.1158/1541-7786.MCR-17-0333. Epub 2017 Sep 18.
25	Immunohistochemical quantification of partial-EMT in oral cavity squamous cell carcinoma primary tumors is associated with nodal metastasis.Oral Oncol. 2019 Dec;99:104458. doi: 10.1016/j.oraloncology.2019.104458. Epub 2019 Nov 6.